LeonaBio, Inc.
No SEC Form 4 filings for $LONA in the last 30 days.
See all $LONA insider activity →LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.
LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lona-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastat
LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001620463 0001620463 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,
Over the past 7 days, alphai's AI scored 2 news stories mentioning LONA (LeonaBio, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent LONA coverage spans earnings and corporate actions.
The beat reduces near-term downside risk, but the bigger driver is continued execution toward ELAINE-3 recruitment completion in Q4 2026 and topline in H2 2027.
Near-term trading focus is ELAINE-3 enrollment progress and the company’s funding runway via cash-exercisable warrants, with additional pipeline updates.
This is routine corporate governance disclosure (annual meeting outcomes) with no new operating, financial, or legal catalyst.
alphai scores every news story that mentions LONA with an AI model for sentiment and relevance, and aggregates insider trades from LeonaBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.
4 min readLeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lona-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastat
6 min readLeonaBio, Inc. (LONA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001620463 0001620463 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,
1 min read
